Close this search box.

A phase II efficacy study of chemo-radiotherapy in PET stage II and III Merkel cell carcinoma of the skin.

This study aims to develop a well-tolerated chemo-radiotherapy treatment for patients with Merkel Cell Carcinoma (MCC) of the skin, which achieves high rates of cancer control. The researchers will be looking at patients' quality of life in those receiving chemotherapy via a questionnaire that will be completed periodically throughout treatment and the follow-up after. The researches will also be looking at the value of using Positron Emission Tomography (PET – a type of imaging procedure that allows us to see anatomical structure and function that cannot usually be seen on a CT scan) to assist in tailoring the Radiation Therapy (RT) treatment plan to the extent of each participants disease.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual


Closing Date of Accrual

January 2016

Trial Chairperson

Associate Professor Michael Poulsen, Mater Centre, QLD

Trial Contact

Clinical Trial Registration

Related Post

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing